Statin Therapeutics in Multiple Sclerosis Management

Statins, widely prescribed for cardiovascular disease, inhibit the enzyme HMG-CoA reductase to lower cholesterol but also exert immunomodulatory and neuroprotective actions. In multiple sclerosis (MS), these pleiotropic effects include suppression of proinflammatory T-cell proliferation, reduction of key cytokines such as interferon-γ and interleukin-17, and attenuation of microglial activation. Imaging studies have used measures of brain atrophy and lesion formation to assess impact on both relapsing-remitting and progressive forms of MS. Early trials of simvastatin in secondary progressive MS demonstrated slowed brain volume loss and modest improvements in disability progression, suggesting potential to delay neurodegeneration. In relapsing-remitting MS, statins have been explored as monotherapy and in combination with interferon β, yielding mixed results on lesion activity and relapse rates. Safety profiles remain favourable at high doses, but transient liver enzyme elevations and muscle symptoms require monitoring. The global significance of repurposing statins lies in their oral administration, low cost and well-characterised safety, offering a complementary approach to existing disease-modifying therapies. Ongoing mechanistic work seeks to clarify cholesterol-independent pathways and optimise statin selection and dosing for different MS phenotypes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Therapeutics in Multiple Sclerosis Management publication trend

The graph below shows the total number of articles in statin therapeutics in multiple sclerosis management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: The rate-limiting enzyme in cholesterol synthesis and the molecular target of all statin drugs.

Expanded Disability Status Scale (EDSS): A clinician-administered scale that quantifies disability in MS across mobility and neurological function.

Brain atrophy: The progressive loss of brain volume detectable by MRI, reflecting neuroaxonal degeneration.

Pleiotropic effects: Additional biological actions of a drug beyond its principal mechanism, such as anti-inflammatory and immunomodulatory effects of statins.

References

1. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet (2014).
2. The Effectiveness of Statins as Potential Therapy for Multiple Sclerosis: A Systematic Review of Randomized Controlled trials. Cureus (2021).
3. Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. PLOS ONE (2008).
4. Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America (2019).
5. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology (2012).
6. Statin Modulation of Human T‐Cell Proliferation, IL‐1β and IL‐17 Production, and IFN‐γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. International Journal of Inflammation (2013).
7. Statins Reduce Lipopolysaccharide‐Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial‐Like Cells. Mediators of Inflammation (2017).
8. Effect of combination of glucocorticoid and different doses of atorvastatin on neural function, blood lipid levels and magnetic resonance imaging in patients wit h multiple sclerosis. Tropical Journal of Pharmaceutical Research (2022).